Analysis and data insight

Biopharmaceutical collaborations: December 2019

January 24, 2020

Biopharma licensings, joint ventures and collaborations, including: Abbvie, Amyris, Athenex, Biocon, Bridgebio, Codexis, Eisai, Eli Lilly, Fulcrum, Genentech, Gilead, Hitgen, Janssen, Kodiak, Ligand, Merck, Mochida, Nicox, Onconova, Pulmatrix, Retrogenix, Sarepta, Sunesis, Tracon, Ultragenyx, Xbiotech

Completed biopharmaceutical mergers & acquisitions: December 2019

January 24, 2020

No Comments

Completed biopharma M&As, including: Astellas, Cambrex, Castle Creek, Dendrimer, Effepharm, Fibrocell, Gemphire, Immunovant, J&J, Kyowa, Neurobo, Permira, Roche, Spark, Taris, Xyphos

Collaborations between biopharmaceutical companies and government/nonprofit entities: December 2019

January 24, 2020

No Comments

Deals between biopharma companies and government or nonprofit entities, including: Abbvie, Advaite, Aptahem, Baergic Bio, Bayer, Bellicum, Bloom Science, EMD Serono, Enochian, Evgen, Hoth, Indivior, Kazia, Regeneron, Sanofi Pasteur, Syntekabio, Theragnostics, Vaccitech

Biopharma money raised: Jan. 1-23, 2020

January 24, 2020

No Comments

Year-to-date money raised in public, private and other financings of biopharma companies.

Money raised by biopharma: 2020 vs. 2019

January 24, 2020

No Comments

Total raised in public, private and other financings of biopharma companies, comparing 2020 vs. 2019.

Precision Medicine World Conference

Novel Dx companies start to see a better path with payers, but continue to work all the angles

January 23, 2020

By Stacy Lawrence

No Comments

SANTA CLARA, Calif. – It has never been easy to get payers to reimburse in a timely and adequate fashion for novel diagnostics, making it notoriously difficult to build a business from them. But a few high-flying diagnostics companies, such as Madison, Wis.-based Exact Sciences Corp. and Redwood City, Calif.-based Guardant Health Inc., have been blazing the trail recently on how to rapidly scale up to become valuable commercial entities from origins as a research-based startup.

Significant year of growth for regenerative medicine sector

January 22, 2020

By Peter Winter

No Comments

According to Janet Lambert, CEO of the Alliance for Regenerative Medicine (ARM), in her delivery of the international advocacy group’s state of the industry briefing at Biotech Showcase in San Francisco, 2019 proved to be a significant year of growth for the regenerative medicine sector.

Quiet conference week, but biopharmas confident about the year ahead

January 21, 2020

By Peter Winter

No Comments

Investors have grown accustomed to hearing news of major announcements from big pharma and blue chip biotech companies during the J.P. Morgan Healthcare conference week. However, as it turned out, headline catalysts were in short supply. In the absence of any major M&A deals taking place, the event turned out to be unusually muted.